NCT00308698

Brief Summary

High recombinant human erythropoietin requirement and elevated serum adiponectin were significant determinants of long-term mortality in patients who started hemodialysis therapy.

Trial Health

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 29, 2006

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 30, 2006

Completed
Last Updated

March 30, 2006

Status Verified

July 1, 2004

First QC Date

March 29, 2006

Last Update Submit

March 29, 2006

Conditions

Renal Dialysis

Keywords

recombinant human erythropoietinadiponectinmortality

Eligibility Criteria

Age0 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • patients who had first started hemodialysis therapy from August 2000 to May 2001 in 11 dialysis centers in Shizuoka prefecture area.

You may not qualify if:

  • nothing particular

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Officials

  • Naro Ohashi, M.D., Ph.D.

    First Department of Medicine, Hamamatsu University School of Medicine

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
DEFINED POPULATION
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

March 29, 2006

First Posted

March 30, 2006

Last Updated

March 30, 2006

Record last verified: 2004-07